Xinli Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5647251/publications.pdf

Version: 2024-02-01

29 papers	786 citations	687363 13 h-index	27 g-index
31	31	31	934
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Integrating Evidence of the Traditional Chinese Medicine Collateral Disease Theory in Prevention and Treatment of Cardiovascular Continuum. Frontiers in Pharmacology, 2022, 13, 867521.	3.5	4
2	Citri Reticulatae Pericarpium alleviates postmyocardial infarction heart failure by upregulating <scp>PPARγ</scp> expression. Clinical and Experimental Pharmacology and Physiology, 2022, 49, 661-673.	1.9	5
3	Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients. Journal of Cardiovascular Translational Research, 2022, 15, 1192-1202.	2.4	4
4	Traditional Chinese Medication Qiliqiangxin Attenuates Diabetic Cardiomyopathy via Activating PPARÎ ³ . Frontiers in Cardiovascular Medicine, 2021, 8, 698056.	2.4	9
5	Nobiletin Attenuates Pathological Cardiac Remodeling after Myocardial Infarction via Activating PPARÎ ³ and PGC1α. PPAR Research, 2021, 2021, 1-17.	2.4	10
6	Study protocol: Traditional Chinese Medicine (TCM) syndrome differentiation for heart failure patients and its implication for long-term therapeutic outcomes of the Qiliqiangxin capsules. Chinese Medicine, 2021, 16, 103.	4.0	9
7	Procalcitonin as an excellent differential marker between uncomplicated and complicated acute appendicitis in adult patients. European Journal of Trauma and Emergency Surgery, 2020, 46, 853-858.	1.7	9
8	Association of aldehyde exposure with cardiovascular disease. Ecotoxicology and Environmental Safety, 2020, 206, 111385.	6.0	29
9	Blood Urea Nitrogen to Creatinine Ratio and Long-Term Mortality in Patients with Acute Heart Failure: A Prospective Cohort Study and Meta-Analysis. CardioRenal Medicine, 2020, 10, 415-428.	1.9	8
10	Citri Reticulatae Pericarpium protects against isoproterenol-induced chronic heart failure via activation of PPARÎ ³ . Annals of Translational Medicine, 2020, 8, 1396-1396.	1.7	17
11	Citri reticulatae Pericarpium attenuates Ang Il-induced pathological cardiac hypertrophy via upregulating peroxisome proliferator-activated receptors gamma. Annals of Translational Medicine, 2020, 8, 1064-1064.	1.7	11
12	Association of aldehydes exposure with obesity in adults. Ecotoxicology and Environmental Safety, 2020, 201, 110785.	6.0	18
13	Study protocol for a randomized controlled trial: Qiliqiangxin in heart failUre: assESsment of reduction in morTality (QUEST). BMC Complementary Medicine and Therapies, 2020, 20, 38.	2.7	8
14	Association between perfluoroalkyl acids and the prevalence of hypertension among US adults. Ecotoxicology and Environmental Safety, 2020, 196, 110589.	6.0	30
15	Qiliqiangxin Attenuates Adverse Cardiac Remodeling after Myocardial Infarction in Ovariectomized Mice via Activation of PPARγ. Cellular Physiology and Biochemistry, 2017, 42, 876-888.	1.6	28
16	Traditional Chinese Medication Qiliqiangxin Protects Against Cardiac Remodeling and Dysfunction in Spontaneously Hypertensive Rats. International Journal of Medical Sciences, 2017, 14, 506-514.	2.5	19
17	The Usage of Heart Failure Biomarkers in China. Cardiovascular Innovations and Applications, 2017, 2, .	0.3	1
18	Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice. American Journal of Translational Research (discontinued), 2017, 9, 5585-5593.	0.0	11

XINLI LI

#	Article	lF	CITATION
19	Qiliqiangxin Attenuates Phenylephrine-Induced Cardiac Hypertrophy through Downregulation of MiR-199a-5p. Cellular Physiology and Biochemistry, 2016, 38, 1743-1751.	1.6	26
20	The Metabolic Effects of Traditional Chinese Medication Qiliqiangxin on H9C2 Cardiomyocytes. Cellular Physiology and Biochemistry, 2015, 37, 2246-2256.	1.6	22
21	Qiliqiangxin Protects Against Cardiac Ischemia-Reperfusion Injury via Activation of the mTOR Pathway. Cellular Physiology and Biochemistry, 2015, 37, 454-464.	1.6	25
22	Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice. Scientific Reports, 2015, 5, 8374.	3.3	64
23	Cardiac ablation of Rheb1 reduces sodium currents in infant mice. International Journal of Clinical and Experimental Medicine, 2014, 7, 947-54.	1.3	1
24	Success rate and safety of coronary angiography and angioplasty via radial artery approach among a Chinese population. Journal of Invasive Cardiology, 2014, 26, 273-5.	0.4	2
25	A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Effects of Qili Qiangxin Capsules in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1065-1072.	2.8	267
26	Genetic and Pharmacological Inhibition of Rheb1-mTORC1 Signaling Exerts Cardioprotection against Adverse Cardiac Remodeling in Mice. American Journal of Pathology, 2013, 182, 2005-2014.	3.8	62
27	Cardiac Ablation of Rheb1 Induces Impaired Heart Growth, Endoplasmic Reticulum-Associated Apoptosis and Heart Failure in Infant Mice. International Journal of Molecular Sciences, 2013, 14, 24380-24398.	4.1	19
28	Future prospects of Qiliqiangxin on heart failure: epigenetic regulation of regeneration. Frontiers in Genetics, 2013, 4, 221.	2.3	12
29	S6K inhibition renders cardiac protection against myocardial infarction through PDK1 phosphorylation of Akt. Biochemical Journal, 2012, 441, 199-207.	3.7	54